Sol-Gel Technologies (NASDAQ:SLGL) Issues Earnings Results

Sol-Gel Technologies (NASDAQ:SLGL) posted its earnings results on Friday. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.27, Zacks reports. Sol-Gel Technologies had a negative net margin of 1,329.13% and a negative return on equity of 56.20%. The firm had revenue of $5.43 million for the quarter, compared to analyst estimates of $1.06 million.

Sol-Gel Technologies Stock Performance

NASDAQ:SLGL opened at $0.44 on Monday. The firm’s fifty day moving average is $0.70 and its 200-day moving average is $0.87. Sol-Gel Technologies has a 52 week low of $0.33 and a 52 week high of $2.99. The firm has a market cap of $12.16 million, a P/E ratio of -0.52 and a beta of 1.54.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on SLGL shares. Raymond James lowered shares of Sol-Gel Technologies from a “strong-buy” rating to an “outperform” rating and reduced their target price for the stock from $6.00 to $4.00 in a report on Monday. HC Wainwright reduced their target price on shares of Sol-Gel Technologies from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, May 20th.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.